



Title	Development of a mouse monoclonal antibody against the chondroitin sulfate-protein linkage region derived from shark cartilage
Author(s)	Akatsu, Chizuru; Fongmoon, Duriya; Mizumoto, Shuji; Jacquinet, Jean-Claude; Kongtawelert, Prachya; Yamada, Shuhei; Sugahara, Kazuyuki
Citation	Glycoconjugate Journal, 27(4), 387-399 <a href="https://doi.org/10.1007/s10719-010-9286-1">https://doi.org/10.1007/s10719-010-9286-1</a>
Issue Date	2010-05
Doc URL	<a href="http://hdl.handle.net/2115/49189">http://hdl.handle.net/2115/49189</a>
Rights	The final publication is available at <a href="http://www.springerlink.com">www.springerlink.com</a>
Type	article (author version)
File Information	GJ27-4_387-399.pdf



[Instructions for use](#)

1 **Development of a mouse monoclonal antibody against the chondroitin**  
2  
3  
4 **sulfate-protein linkage region derived from shark cartilage**  
5  
6  
7  
8  
9

10 **Chizuru Akatsu, Duriya Fongmoon, Shuji Mizumoto, Jean-Claude Jacquinet, Prachya**  
11  
12  
13 **Kongtawelert, Shuhei Yamada, and Kazuyuki Sugahara**  
14  
15  
16  
17  
18  
19

20 **Abstract**  
21  
22

23 Glycosaminoglycans (GAGs) like chondroitin sulfate (CS) and heparan sulfate (HS) are  
24  
25 synthesized on the tetrasaccharide linkage region, GlcA $\beta$ 1-3Gal $\beta$ 1-3Gal $\beta$ 1-4Xyl $\beta$ 1-*O*-Ser, of  
26  
27 proteoglycans. The Xyl can be modified by 2-*O*-phosphate in both CS and HS, whereas the Gal  
28  
29 residues can be sulfated at C-4 and/or C-6 in CS but not in HS. To study the roles of these  
30  
31 modifications, monoclonal antibodies were developed against linkage glycopeptides of shark  
32  
33 cartilage CS proteoglycans, and one was characterized in detail. This antibody bound hexa- and  
34  
35 pentasaccharide-peptides more strongly than tetrasaccharide-peptides, suggesting the importance of  
36  
37 GalNAc. It did not react to the CS linkage region modified by 4-*O*-sulfation. Its reactivity was not  
38  
39 affected by treatment with chondro-4-sulfatase or alkaline phosphatase. The results of an ELISA  
40  
41 using various proteoglycans and glycopeptides with different modifications suggested the  
42  
43 recognition of 6-*O*-sulfate on the GalNAc and/or Gal residues. Treatments with exopeptidases did  
44  
45 not affect the reactivity of the hexasaccharide-peptide fraction, whereas weak alkali to cleave the  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Xyl-Ser linkage completely abolished the binding activity, suggesting the importance of the Xy-Ser  
2  
3  
4 linkage for the binding. Furthermore, the antibody stained wild-type CHO cells, but not mutant cells  
5  
6  
7 deficient in xylosyltransferase required for the synthesis of the linkage region. These results suggest  
8  
9  
10 that the antibody recognizes the structure GalNAc-GlcA-Gal-Gal-Xyl-Ser that is modified by  
11  
12  
13 6-*O*-sulfation on GalNAc and/or Gal. The antibody will be a useful tool for investigating the  
14  
15  
16 significance of the linkage region in the biosynthesis and/or intracellular transport of different GAG  
17  
18  
19 chains.  
20  
21  
22  
23  
24  
25

26 **Keywords** Proteoglycans, Glycosaminoglycans, Chondroitin sulfate, Heparan sulfate, Dermatan  
27  
28  
29 sulfate, Monoclonal antibody  
30  
31  
32  
33  
34  
35

### 36 **Abbreviations**

37  
38  
39 2AB, 2-aminobenzamide; BSA, bovine serum albumin; CS, chondroitin sulfate; DS, dermatan  
40  
41  
42 sulfate; ELISA, enzyme-linked immunosorbent assay; GAG, glycosaminoglycan; Gal, D-galactose;  
43  
44  
45 GalNAc, *N*-acetyl-D-galactosamine; GlcA, D-glucuronic acid; GlcN, D-glucosamine; GlcNAc,  
46  
47  
48 *N*-acetyl-D-glucosamine; Hep, Heparin;  $\Delta$ HexA, 4,5-unsaturated hexuronic acid or  
49  
50  
51 4-deoxy- $\alpha$ -L-*threo*-hex-4-enopyranosyluronic acid; HPLC, high performance liquid chromatography;  
52  
53  
54  
55 HS, heparan sulfate; IdoA, L-iduronic acid; PG, proteoglycan; Xyl, D-xylose.  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## 1 Introduction

2  
3  
4 Proteoglycans (PGs) are macromolecules composed of linear polysaccharide  
5  
6  
7 glycosaminoglycan (GAG) side chains, which are covalently attached to specific Ser residues of core  
8  
9  
10 proteins. PGs are distributed mainly in extracellular matrices and at cell surfaces, and implicated in  
11  
12  
13 many pathophysiological phenomena. Characteristic GAG moieties appear to play important roles as  
14  
15  
16 regulators of various biological processes by interacting with functional protein ligands such as  
17  
18  
19 growth factors, cytokines, and morphogens [1-4].  
20  
21

22  
23 GAGs include chondroitin sulfate/dermatan sulfate (CS/DS) and heparan sulfate/heparin  
24  
25  
26 (HS/Hep), which are classified as galactosaminoglycans and glucosaminoglycans, respectively.  
27  
28  
29 CS/DS and HS/Hep consist of repeating disaccharide units, GlcA/IdoA-GalNAc and  
30  
31  
32 GlcA/IdoA-GlcN/GlcNAc, respectively. GlcA, IdoA, GalNAc, GlcN, and GlcNAc represent  
33  
34  
35 D-glucuronic acid, L-iduronic acid, *N*-acetyl-D-galactosamine, D-glucosamine, and  
36  
37  
38 *N*-acetyl-D-glucosamine, respectively. GAGs are specifically modified most notably by sulfation at  
39  
40  
41 various positions, forming a variety of structures and acquiring functions. Although the structure of  
42  
43  
44 the repeating disaccharide region differs between CS/DS and HS/Hep, both types of GAGs are  
45  
46  
47 covalently bound to core proteins through the common linkage region tetrasaccharide,  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

In the biosynthesis of GAGs, monosaccharide residues are transferred stepwise from the

1 corresponding nucleotide sugars to growing GAG chains, being governed largely by the substrate  
2  
3  
4 specificity of the glycosyltransferases involved. This process is initiated by the addition of Xyl to  
5  
6  
7 specific serine residues in the core protein, followed by the sequential addition of two Gal residues  
8  
9  
10 and a GlcA residue to construct the tetrasaccharide linkage structure [1]. The synthesis of CS/DS  
11  
12  
13 chains initiates once GalNAc is transferred by the *N*-acetylgalactosaminyltransferase-I (GalNAcT-I)  
14  
15  
16 activity of chondroitin synthases to the GlcA of the common linkage region, whereas that of HS/Hep  
17  
18  
19 chains initiates if GlcNAc is first added by the *N*-acetylglucosaminyltransferase-I (GlcNAcT-I)  
20  
21  
22 activity [1, 4, 6]. Hence, GalNAcT-I and GlcNAcT-I activities are crucial for the determination of  
23  
24  
25 the GAG species to be synthesized on the common tetrasaccharide linkage region. However, it is not  
26  
27  
28 clear how these different GAGs are selectively assembled on the common structure.  
29  
30

31  
32 We have carried out a series of structural studies of the GAG-protein linkage region, based  
33  
34  
35 on the working hypothesis that there may be differences in the region's structure among GAG chains  
36  
37  
38 and such differences may contribute to the determination of the type and/or character of the GAG  
39  
40  
41 species to be synthesized [6, 7]. These structural studies have revealed unique modifications, such as  
42  
43  
44 4-*O*-sulfated Gal, 6-*O*-sulfated Gal, and 2-*O*-phosphorylated Xyl. So far, sulfated Gal residues have  
45  
46  
47 been demonstrated only in the linkage region of CS/DS, not in HS/Hep, though a  
48  
49  
50 2-*O*-phosphorylated Xyl residue has been found in both CS/DS and HS/Hep [6, 8, 9], suggesting the  
51  
52  
53 sulfate groups on the Gal residues to be involved in the selective assembly of different GAG types.  
54  
55  
56 In fact, it has been demonstrated that these modifications influence the catalytic activities of  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 galactosyltransferase-I, which transfers Gal-2 (for the numbering of the sugar residues, see Table 1),  
2  
3  
4 and glucuronyltransferase-I (GlcAT-I), which transfers the first GlcA, involved in the construction of  
5  
6  
7 the tetrasaccharide linkage region [10, 11]. However, it is not fully understood if these modifications  
8  
9  
10 also affect on other biosynthetic enzymes or play a biological role as recognition signals for  
11  
12  
13 regulatory proteins such as intracellular transporters.  
14  
15

16  
17 The use of antibodies has become a standard approach in many fields of biochemical and  
18  
19  
20 biomedical research. To clarify the biological significance of the modifications in the GAG-protein  
21  
22  
23 linkage region, antibodies which recognize specific patterns of modification in the region may be  
24  
25  
26 useful. Monoclonal antibodies (mAbs) that recognize specific features of the repeating disaccharide  
27  
28  
29 region of CS chains have been generated, and epitopes of some of them have been characterized  
30  
31  
32 [12-16]. Studies using anti-CS mAbs have revealed restricted spatiotemporal patterns of the  
33  
34  
35 expression of specific CS structures in various tissues during growth and development, and in  
36  
37  
38 pathological conditions [16-19]. However, so far, no antibodies have been reported which recognize  
39  
40  
41 the GAG-protein linkage region. In the present study, a mAb against the CS-protein linkage region  
42  
43  
44 from shark cartilage was developed and its epitope was characterized.  
45  
46  
47  
48  
49  
50

## 51 **Materials and methods**

52  
53  
54  
55 *Materials* PGs from salmon nasal cartilage, chicken cartilage, and whale cartilage were provided by  
56  
57  
58 Biomatec Japan Inc. (Kushiro, Japan). PG from rayfish cartilage was obtained from Marukyou  
59  
60

1 Biofoods Co., Ltd. (Kushiro, Japan). PG from birds' nests made with dried saliva of male *Collocalia*  
2  
3  
4 swiftlets was provided by Y. T. Li, Tulane University [20]. PG from bovine nasal cartilage was a gift  
5  
6  
7 from the late Dr. Albert Dorfman, University of Chicago. A whale cartilage CS-peptide fraction,  
8  
9  
10 which contained Ser, Asp, Thr, Glu, Pro, Gly, Ala, Val, Lys and Arg in a molar ratio of 1.00 : 1.74 :  
11  
12  
13 0.42 : 1.99 : 1.53 : 4.22 : 1.00 : 0.52 : 0.63 : 0.65, was prepared as reported [21].  
14  
15

16  
17 The following enzymes were purchased from Seikagaku Corp. (Tokyo, Japan):  
18  
19  
20 chondroitinase (CSase) ABC (EC 4.2.2.20) from *Proteus vulgaris*, CSase AC-I (EC 4.2.2.5) from  
21  
22  
23 *Fravobacterium heparinum*, CSase AC-II (EC 4.2.2.5) from *Artherobacter aurescens*, and  
24  
25  
26 chondro-4-sulfatase (EC 3.1.6.9) from *P. vulgaris*. Aminopeptidase M (EC 3.4.11.2) from porcine  
27  
28  
29 kidney, carboxypeptidase Y (EC 3.4.16.5) from yeast, and calf intestinal alkaline phosphatase (EC  
30  
31  
32 3.1.3.1) of special quality for molecular biology were obtained from EMD Biosciences, Inc. (San  
33  
34  
35 Diego, CA), Oriental Yeast Co., Ltd. (Tokyo, Japan), and Boehringer Mannheim GmbH (Mannheim,  
36  
37  
38 Germany), respectively. Anti-HS antibody F58-10E4 and Alexa Fluor 488<sup>®</sup>-labeled goat anti-mouse  
39  
40  
41 IgM antibody were purchased from Seikagaku Corp. (Tokyo, Japan) and Molecular Probes (Eugene,  
42  
43  
44 OR), respectively. Synthetic peptides, Leu-*p*-nitroanilide and benzyloxycarbonylglycyl-Phe, were  
45  
46  
47 purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan) and Peptide Institute, Inc.  
48  
49  
50 (Osaka, Japan), respectively.  
51  
52  
53

54  
55 Wild-type Chinese hamster ovary (CHO) cells (CHO-K1) and xylosyltransferase-deficient  
56  
57  
58 CHO cells (pgsA-745) [22] were purchased from American Type Culture Collection (Manassas, VA).  
59  
60

1 These cell lines were maintained in Ham's F12K medium (Wako Pure Chemical Industries, Ltd.,  
2  
3  
4 Osaka, Japan) supplemented with 10% heat-inactivated fetal bovine serum at 37 °C in a humidified  
5  
6  
7 atmosphere containing 5% CO<sub>2</sub>.

8  
9  
10 The Structurally defined linkage hexasaccharide  
11  
12  $\Delta$ HexA-GalNAc(4-*O*-sulfate)-GlcA-Gal(4-*O*-sulfate)-Gal-Xyl was isolated from whale cartilage  
13  
14 CS-PG [23].  $\Delta$ HexA stands for 4,5-unsaturated hexuronic acid. A 2-aminobenzamide  
15  
16  
17 (2AB)-derivative of the linkage hexasaccharide  
18  
19  
20  $\Delta$ HexA-GalNAc-GlcA-Gal-Gal-Xyl(2-*O*-phosphate)-2AB, was prepared as described previously  
21  
22  
23 [23]. The tetrasaccharide peptide GlcA-Gal-Gal-Xyl(2-*O*-phosphate)-Ser-Gly was chemically  
24  
25  
26 synthesized [24].  
27  
28  
29  
30

31  
32  
33  
34  
35  
36 *Preparation of the oligosaccharide-peptides from the CS-core protein linkage region* The CS-peptide  
37  
38  
39 fraction (1.0 g) was prepared from shark cartilage [25, 26] and exhaustively digested with 1.2 IU of  
40  
41  
42 CSase ABC in a total volume of 12.5 ml of 50 mM Tris/HCl buffer, pH 8.0, containing 60 mM  
43  
44  
45 sodium acetate and 0.1% bovine serum albumin (BSA) for 25 h at 37 °C. An additional 0.2 IU of the  
46  
47  
48 enzyme was added after 23 h to complete the digestion, and the reaction was terminated by heating at  
49  
50  
51 100 °C for 5 min. The digest was fractionated by gel filtration using a column (2.0 X 149 cm) of  
52  
53  
54 Sephadex G-15 (GE Healthcare, Buckinghamshire, UK) with 0.25 M NH<sub>4</sub>HCO<sub>3</sub>/7% 1-propanol as  
55  
56  
57 the eluent. The isolated linkage hexasaccharide-peptide fraction was digested with CSase ABC again  
58  
59



1 as described above to complete the digestion, and this process was repeated three times until no  
2  
3  
4 disaccharide was produced as judged by gel filtration chromatography. This fraction contained  
5  
6  
7 several amino acids including Ser, Glu, Pro, Gly, Val, and Lys in a molar ratio of 1.00, 1.16, 1.41,  
8  
9  
10 1.23, 0.46, and 0.29, respectively [25].  
11

12  
13 To eliminate the  $\Delta$ HexA residue, which has strong immunogenic activity, from the  
14  
15  
16 nonreducing end of the linkage hexasaccharide-peptides, the glycopeptides were treated with mercuric  
17  
18  
19 acetate as described previously [27, 28]. Namely, the linkage hexasaccharide-peptide fraction (1.5  
20  
21  
22  $\mu$ mol as linkage hexasaccharide) was treated with 0.2 ml of 10 mM mercuric acetate in 130 mM  
23  
24  
25 sodium acetate buffer, pH 5.0, overnight at room temperature. After the addition of 2 ml of 5 M NaCl,  
26  
27  
28 the reaction mixture was desalted by successive gel filtration using a Sephadex G-25 (fine) column  
29  
30  
31 (1.5 X 47 cm) equilibrated with 1 M NaCl and then with H<sub>2</sub>O.  
32  
33  
34

35  
36 The linkage tetrasaccharide-peptides were prepared by treatment of the linkage  
37  
38  
39 hexasaccharide-peptides (120 nmol as  $\Delta$ HexA) with 10 mIU of CSase AC-I [29] in a total volume of  
40  
41  
42 30  $\mu$ l of 50 mM of Tris/HCl buffer, pH 7.3, at 37 °C for 20 h. The enzymatic reaction was terminated  
43  
44  
45 by heating at 95 °C for 1 min.  
46  
47

48  
49 The linkage oligosaccharide-peptide fraction was treated with LiOH as described below to  
50  
51  
52 release the oligosaccharide from the core peptides, labeled with 2AB and analyzed by anion  
53  
54  
55 exchange HPLC on an amine-bound silica PA-03 column (4.6 X 250 mm, YMC Co., Kyoto, Japan)  
56  
57  
58 to confirm the presence of the linkage oligosaccharide components predicted. The molar  
59  
60

1 concentration of the linkage oligosaccharide-peptides was determined by measuring absorbance at  
2  
3  
4 232 nm based on an average millimolar absorption coefficient of 5.5 for the double bond of  $\Delta$ HexA  
5  
6  
7 [30] or by the carbazole reaction to measure uronic acids (GlcA and  $\Delta$ HexA) colorimetrically [31].  
8  
9

10  
11  
12  
13 *Production of the monoclonal antibody* Monoclonal antibodies were generated by immunizing  
14  
15  
16 BALB/c mice with the linkage pentasaccharide-peptide fraction from shark cartilage CS. The linkage  
17  
18  
19 pentasaccharide-peptide fraction was conjugated with a carrier protein, keyhole limpet hemocyanin  
20  
21  
22 (KLH) (Sigma, St Louis, MO), using glutaraldehyde [32], which cross-links primary amino groups  
23  
24  
25 of peptides as described below: 1  $\mu$ mol of the fraction was conjugated with 4 mg of KLH in 2 ml of  
26  
27  
28 phosphate-buffered saline (PBS), pH 7.2, with the addition of glutaraldehyde to a final concentration  
29  
30  
31 of 0.1% at room temperature overnight. The reaction was terminated by addition of 0.25 ml of 1 M  
32  
33  
34 glycine, and then the conjugates were dialyzed overnight against PBS. The KLH-conjugated linkage  
35  
36  
37 pentasaccharide-peptide fraction was injected into mice at 20  $\mu$ g/injection every 2 weeks. After the  
38  
39  
40 fourth injection, the serum was screened for reactivity with the linkage hexasaccharide-peptides.  
41  
42  
43  
44 Spleen B lymphocytes of the positive mice were isolated and fused with myeloma cells. The culture  
45  
46  
47 supernatant of the fused hybridoma cells was screened by enzyme-linked immunosorbent assay  
48  
49  
50 (ELISA) using the linkage hexasaccharide-peptides, and three positive clones, 4E1, 3F11, and 1B5,  
51  
52  
53  
54 were selected. The clone 4E1 with the highest specificity toward the linkage hexasaccharide-peptide  
55  
56  
57 fractions was recloned, and eleven secondary clones were further selected. Among the eleven clones,  
58  
59  
60

1 six showed high specificity and were injected intraperitoneally into mice to obtain ascitic fluid.

2  
3  
4 Antibody subclasses were determined using the ImmunoPure<sup>®</sup> Monoclonal Antibody Isotyping Kit  
5  
6  
7 II (Pierce Biotechnology, Rockford, IL). The mAb 4E1/D6 was of particular interest because of its  
8  
9  
10 specific activity, and subsequently characterized in detail.  
11  
12  
13  
14  
15

16  
17 *ELISA* The specificity of the antibody 4E1/D6 in terms of antigen recognition was tested by ELISA.  
18  
19  
20 Briefly, various PG preparations or linkage oligosaccharide-peptide fractions (0.5 µg each) were  
21  
22  
23 dissolved in a 0.2 M sodium bicarbonate buffer, pH 9.6 and individually immobilized overnight to a  
24  
25  
26 96-well microtiter plate (Nunc immune plate, MaxiSorp, Nalge Nunc International, Rochester, NY)  
27  
28  
29 at room temperature. The wells were washed once with PBS, pH 7.4, containing 0.05% Tween 20  
30  
31  
32 (PBST), and blocked with 3% (w/v) BSA in PBS for 1 h at 37 °C. The wells were then washed with  
33  
34  
35  
36 PBST once and incubated with 4E1/D6 for 2 h at 37 °C. After three washes with 25 mM  
37  
38  
39 Tris-buffered saline (TBS) containing 0.05% Tween20 (TBST), the wells were incubated with  
40  
41  
42 alkaline phosphatase-labeled anti-mouse Ig(G+M) (3,000-fold dilution, Chemicon, San Diego, CA).  
43  
44  
45 Enzymatic activity was detected using *p*-nitrophenylphosphate by measuring the absorbance at 415  
46  
47  
48 nm.  
49  
50

51  
52 For the competitive ELISA, aliquots of the linkage hexasaccharide-peptides from shark  
53  
54  
55 cartilage CS, which had been pretreated with peptidase or LiOH, was incubated with 4E1/D6 in a  
56  
57  
58 total volume of 50 µL at 37 °C for 1 h, then the mixture was applied to the wells where untreated  
59  
60

1 linkage hexasaccharide-peptides from shark cartilage CS had been immobilized. The color was  
2  
3  
4 developed as described above.  
5  
6  
7  
8  
9

10 *Chemical and enzymatic treatments of the linkage hexasaccharide-peptide fraction* To liberate  
11  
12 *O*-linked linkage oligosaccharides from the core peptides, treatment with LiOH was performed as  
13  
14 described previously [23, 33]. Briefly, the hexasaccharide-peptide fraction (183 nmol) was treated  
15  
16  
17 with 0.5 M LiOH at 4°C for 15 h. The reaction was terminated by neutralization with 2.0 M acetic  
18  
19  
20 acid, and then Li<sup>+</sup> was removed by cation-exchange chromatography using AG 50W-X2 resin  
21  
22  
23 (Bio-Rad Laboratories, Hercules, CA).  
24  
25  
26  
27  
28

29  
30 Aminopeptidase M or carboxypeptidase Y digestion was carried out using 10 nmol of the  
31  
32 linkage hexasaccharide-peptide fraction and 3 U of each enzyme in 10 µl of 25 mM imidazole/HCl  
33  
34  
35 buffer, pH 7.6, or 50 mM phosphate buffer, pH 6.0, respectively, for 30 min at 37°C.  
36  
37  
38

39 To investigate the reactivity of the antibody 4E1/D6 to the 4-*O*-sulfated or  
40  
41  
42 2-*O*-phosphorylated linkage structure, treatment with chondro-4-sulfatase or alkaline phosphatase  
43  
44  
45 was conducted. One nmol of the linkage hexasaccharide-peptide fraction or a structurally defined  
46  
47  
48 linkage hexasaccharide, ΔHexA-GalNAc(4-*O*-sulfate)-GlcA-Gal(4-*O*-sulfate)-Gal-Xyl, was digested  
49  
50  
51 with the indicated enzyme. Digestion with chondro-4-sulfatase was performed with 12 mIU of the  
52  
53  
54 enzyme for 6 h in 3 µL of 50 mM Tris/HCl buffer, pH 7.5, containing 50 mM sodium acetate [34].  
55  
56  
57  
58 Treatment with alkaline phosphatase was carried out with 1 IU of the enzyme in a total volume of 3  
59  
60  
61  
62  
63  
64  
65

1  $\mu$ L of the buffer supplied by the manufacturer at 37 °C for 6 h.  
2  
3  
4  
5  
6

7 *Immunofluorescence flow cytometry* CHO-K1 and pgsA-745 cells were detached with 2 mM EDTA  
8  
9  
10 and suspended in PBS containing 0.1% BSA (PBS-BSA) at a concentration of  $10^6$  cells/ml. After  
11  
12  
13 three washes with PBS-BSA, the cells were incubated with the antibody 4E1/D6 (400-fold dilution)  
14  
15  
16 or a commercial antibody F58-10E4 against HS (200-fold dilution) at 4°C for 30 min. The cells were  
17  
18  
19 washed with PBS-BSA three times and incubated with Alexa Fluor 488<sup>®</sup>-labeled goat anti-mouse  
20  
21  
22 IgM antibody (500-fold dilution). After three washes with PBS-BSA, the cells were analyzed by  
23  
24  
25 immunofluorescence flow cytometry in a BD FACSCanto (BD Biosciences, San Jose, CA). Flow  
26  
27  
28 cytometric data were analyzed using Flowjo software (Tree Star, Inc., Ashland, OR).  
29  
30  
31  
32  
33  
34  
35

## 36 **Results**

37  
38

39 *Production of the monoclonal antibody against the linkage oligosaccharide-peptide fraction of shark*  
40  
41  
42 *cartilage CS* The CS-peptide fraction of shark cartilage was exhaustively digested with CSase ABC  
43  
44  
45 to prepare the linkage hexasaccharide-peptide fraction. Approximately 9.2  $\mu$ mol of this fraction was  
46  
47  
48 obtained and an aliquot was analyzed by anion-exchange HPLC on an amine-bound silica PA-03  
49  
50  
51 column after cleavage of the bond between the xylose and the serine using LiOH [23, 33] (results not  
52  
53  
54 shown). The fraction contained at least thirteen hexasaccharide compounds as reported (Table 1) [25,  
55  
56  
57 26]. Since the glycopeptides contain a  $\Delta$ HexA residue at the nonreducing terminus, which is an  
58  
59  
60  
61  
62  
63  
64  
65

1 unnatural structure causing strong antigenicity, the  $\Delta$ HexA residue was eliminated by treatment with  
2  
3  
4 mercuric acetate [27, 28]. The pentasaccharide-peptide fraction was conjugated with KLH and used  
5  
6  
7 as an immunogen to develop mAbs against the CS-core protein linkage region.  
8  
9

10 After immunization of BALB/c mice with the immunogen, six positive clones were  
11  
12  
13 obtained by screening assays using the CS hexasaccharide-peptide fraction immobilized onto a Nunc  
14  
15  
16 Maxisorp plate. Clone 4E1/D6, with the highest level of activity, was characterized further. This  
17  
18  
19 clone contained an IgM-type immunoglobulin with kappa light chains (data not shown), and the  
20  
21  
22 concentration of protein in ascitic fluid was 34.3 mg/ml as determined using the BCA protein assay  
23  
24  
25 kit according to the instructions provided by the manufacturer (Thermo Scientific, Rockford, IL).  
26  
27  
28  
29  
30  
31

32 *Assessment of the reactivity of the antibody 4E1/D6 toward various PGs* To characterize the  
33  
34  
35 specificity of 4E1/D6, the antibody's reactivity toward various PGs was assessed by ELISA (Fig. 1),  
36  
37  
38 where PGs were individually immobilized onto a Nunc Maxisorp plate through their protein moiety.  
39  
40  
41 The linkage hexasaccharide-peptide fraction from shark cartilage CS was also immobilized as a  
42  
43  
44 positive control. Significant binding of 4E1/D6 was observed with the linkage hexasaccharide  
45  
46  
47 fraction and a PG from salmon nasal cartilage, but with no other PGs tested. The reactivity of  
48  
49  
50 4E1/D6 toward this PG was confirmed by a competitive ELISA: a soluble PG from salmon nasal  
51  
52  
53 cartilage inhibited the binding of 4E1/D6 to the immobilized linkage hexasaccharide-peptide fraction  
54  
55  
56 of shark cartilage CS in a dose-dependent manner (data not shown). 4E1/D6 reacted less extensively  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 to the salmon PG than the linkage hexasaccharide-peptide fraction and not at all to the other PGs  
2  
3  
4 tested. Of course, the possibility exists that the linkage regions of these PGs are masked by CS  
5  
6  
7 polysaccharide side chains, and so are inaccessible to the antibody. However, the structural  
8  
9  
10 difference among these PGs remains investigated.  
11

12  
13  
14  
15  
16 *Assessment of the reactivity of 4E1/D6 toward the linkage region oligosaccharides* To investigate the  
17  
18  
19 structural features of the linkage pentasaccharide-peptides required for recognition by 4E1/D6, the  
20  
21  
22 reactivity of 4E1/D6 toward linkage hexa-, penta-, and tetrasaccharide-peptide fractions of shark  
23  
24  
25 cartilage CS was assessed by ELISA (Fig. 2). The linkage tetrasaccharide-peptide fraction was  
26  
27  
28 prepared by digestion of the linkage hexasaccharide-peptide fraction with CSase AC-I, and the  
29  
30  
31 exhaustive digestion was confirmed by gel filtration chromatography of the digest. The linkage hexa-,  
32  
33  
34 penta-, and tetrasaccharide-peptide fractions (0.5 µg each) were immobilized onto Maxisorp plates.  
35  
36  
37 The reactivity was considerably weaker toward the tetrasaccharide-peptides than hexa- or  
38  
39  
40 pentasaccharide-peptides of shark cartilage CS (Table 1). These results suggest the fifth saccharide  
41  
42  
43 residue GalNAc-5 in the linkage oligosaccharide-peptide fraction to be important for recognition by  
44  
45  
46 4E1/D6. In strong contrast, the hexasaccharide-peptide fraction of whale cartilage CS, which  
47  
48  
49  
50 contains four major saccharide sequences with different sulfation patterns (Table 1), showed no  
51  
52  
53 reactivity, suggesting that the 4E1/D6 epitope may contain a particular modification in the linkage  
54  
55  
56 region. In addition, 4E1/D6 may distinguish the different amino acid sequences in the peptide moiety  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 of the linkage oligosaccharide-peptide of shark cartilage CS from those of whale cartilage CS (see  
2  
3  
4 above).

10 *Assessment of the reactivity of 4E1/D6 toward the peptide moiety of the linkage*

13 *hexasaccharide-peptides* To assess whether 4E1/D6 recognizes the peptide moiety of the linkage

16 hexasaccharide-peptides, a competitive ELISA was carried out using the linkage hexasaccharide

19 fraction from shark cartilage CS treated with LiOH, aminopeptidase, or carboxypeptidase as an

22 inhibitor (Fig. 3). Treatment with LiOH liberates hexasaccharides from the core peptide. Upon

25 treatment with aminopeptidase or carboxypeptidase, amino acid residues located on the amino or

28 carboxy terminal side of the Ser residue are trimmed, respectively. The LiOH-treated sample did not

31 inhibit at all the binding of 4E1/D6 to the linkage hexasaccharide-peptides of shark cartilage CS. In

34 contrast, the digest of the linkage hexasaccharide fraction obtained with aminopeptidase or

37 carboxypeptidase inhibited the binding of 4E1/D6 to the un-treated linkage hexasaccharide-peptide

40 to a comparable degree with the linkage hexasaccharide-peptides of shark cartilage CS (Fig. 3). The

43 activities of aminopeptidase and carboxypeptidase were confirmed by colorimetric assays using the

46 artificial substrates Leu-*p*-nitroanilide and benzyloxycarbonylglycyl-Phe, respectively [35, 36]. From

49 these results, 4E1/D6 does not appear to recognize sequences composed of multiple amino acids.

52 Rather, the xylosidic linkage to the Ser residue appears to be recognized by 4E1/D6. The possibility

55 exists that a few amino acids immediately adjacent to the Ser residue are also recognized since in



1 amino acid composition, the hexasaccharide peptide fractions derived from shark and whale cartilage  
2  
3  
4 CS differ considerably (see above).  
5  
6  
7  
8  
9

10 *Assessment of the reactivity of 4E1/D6 to the sulfatase- or phosphatase-treated linkage*

11 *hexasaccharide-peptide fraction* Since 4E1/D6 did not react to the hexasaccharide-peptide fraction  
12  
13  
14 of whale cartilage CS (Fig. 2), it seems to recognize a sulfated or phosphorylated component of the  
15  
16  
17 pentasaccharide-peptide fraction of shark cartilage CS. GalNAc and two Gal residues can often be  
18  
19  
20 modified by 6-*O*-sulfate, and Xyl can be modified by 2-*O*-phosphate. In addition, GalNAc-5 and  
21  
22  
23 Gal-3 can be sulfated at position C-4. Therefore, to examine whether 4-*O*-sulfation and  
24  
25  
26 2-*O*-phosphorylation in the linkage region are required for the epitope's recognition, the reactivity of  
27  
28  
29 4E1/D6 toward the linkage hexasaccharide-peptide fraction was investigated by ELISA before and  
30  
31  
32 after digestion with chondro-4-sulfatase or alkaline phosphatase (Fig. 4). The reactivity of 4E1/D6  
33  
34  
35 toward the hexasaccharide-peptide fraction was not diminished after either treatment, suggesting that  
36  
37  
38 neither the 4-*O*-sulfate nor 2-*O*-phosphate group is recognized by 4E1/D6. The enzymatic activity of  
39  
40  
41 chondro-4-sulfatase and alkaline phosphatase toward the linkage region was confirmed by digestion  
42  
43  
44 of the structurally defined linkage hexasaccharides. As shown in Fig. 5, after treatment with  
45  
46  
47 chondro-4-sulfatase, the position of the disulfated linkage hexasaccharide  
48  
49  
50  $\Delta$ HexA-GalNAc(4-*O*-sulfate)-GlcA-Gal(4-*O*-sulfate)-Gal-Xyl (Fig. 5A, closed arrow) shifted to that  
51  
52  
53 position of the nonsulfated linkage hexasaccharide  $\Delta$ HexA-GalNAc-GlcA-Gal-Gal-Xyl (Fig. 5B,  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 open arrow). Digestion of the 2AB-derivative of the phosphorylated hexasaccharide,  
2  
3  
4  $\Delta$ HexA-GalNAc-GlcA-Gal-Gal-Xyl(2-*O*-phosphate)-2AB, with alkaline phosphatase yielded  
5  
6  
7  $\Delta$ HexA-GalNAc-GlcA-Gal-Gal-Xyl-2AB as judged by anion-exchange HPLC (data not shown). The  
8  
9  
10 recognition of the 2-*O*-phosphorylated linkage region by 4E1/D6 was also examined by competitive  
11  
12  
13 ELISA using a chemically synthesized linkage tetrasaccharide-peptide,  
14  
15  
16 GlcA-Gal-Gal-Xyl(2-*O*-phosphate)-Ser-Gly [24], as an inhibitor. However, it showed no inhibitory  
17  
18  
19 activity. No sulfatase which hydrolyzes 6-*O*-sulfate groups in the linkage region is available, and  
20  
21  
22 therefore it is not possible to investigate whether the 6-*O*-sulfate groups are recognized. The  
23  
24  
25 commercial bacterial chondro-6-sulfatase (Seikagaku Corp.) does not act on the 6-*O*-sulfate groups  
26  
27  
28 of the Gal residues in the linkage region [34].  
29  
30  
31  
32  
33  
34  
35

36 *Analysis of the interactions of 4E1/D6 with CHO cell lines deficient in the biosynthetic enzymes for*  
37  
38  
39 *the linkage region of GAGs* The specificity of 4E1/D6 was investigated further by analyzing its  
40  
41  
42 interaction with two CHO cell lines, CHO-K1 and pgsA-745, using immunofluorescence  
43  
44  
45 flowcytometry. The pgsA-745 is a mutant cell line deficient in xylosyltransferase, and was  
46  
47  
48 established from CHO-K1 cells (wild type) [22]. In the biosynthesis of CS and HS, a  
49  
50  
51 xylosyltransferase initiates the formation of the tetrasaccharide linkage region by transferring a Xyl  
52  
53  
54 residue to a specific Ser residue of the core protein. The pgsA-745 cells produce neither CS nor HS  
55  
56  
57 polysaccharide chains since they cannot construct the linkage region, which is common to CS and  
58  
59  
60

1 HS. Although no immunoreactivity with pgsA-745 cells was detected (Fig. 7B, light gray  
2  
3  
4 histograms), weak but significant immunoreactivity with CHO-K1 cells was (Fig. 7A, light gray  
5  
6  
7 histogram), suggesting the epitope of 4E1/D6 to exist on the surface of wild-type CHO cells but not  
8  
9  
10 the mutant cells. A HS-specific antibody, F58-10E4, was used as a positive control, and as expected,  
11  
12  
13 intensely stained CHO-K1 cells but did not stain pgsA-745 cells (Fig. 7, dark gray histograms).  
14  
15  
16  
17  
18  
19

## 20 Discussion

21  
22  
23 Galactosaminoglycans (CS/DS) and glucosaminoglycans (HS/Hep) are synthesized at  
24  
25  
26 specific Ser residues of the core proteins of PGs through the tetrasaccharide linkage region  
27  
28  
29  $\text{GlcA}\beta 1\text{-3Gal}\beta 1\text{-3Gal}\beta 1\text{-4Xyl}$  [5]. Although the tetrasaccharide core is common to CS/DS and  
30  
31  
32 HS/Hep, the pattern of modification in the linkage region differs between the two types of GAG  
33  
34  
35 chains. Namely, the 4-*O*-sulfation of a Gal-3 residue and 6-*O*-sulfation of both Gal-2 and Gal-3  
36  
37  
38 residues have been found in CS/DS, but not HS/Hep. Interestingly, syndecan-1, a hybrid-type PG  
39  
40  
41 bearing both HS and CS chains, carries a 4-*O*-sulfate on the Gal-3 of only the CS chains [9],  
42  
43  
44 supporting the notion that 4-*O*-sulfation is a modification specific to CS chains [7]. In contrast,  
45  
46  
47 phosphorylation occurs on the Xyl of both CS/DS and HS/Hep [9]. Interestingly, these modifications  
48  
49  
50 have significant effects on the synthesis of the tetrasaccharide linkage region. The phosphate on Xyl  
51  
52  
53 stimulates the attachment of the first GlcA-4 [10, 11], but then seems to be removed [37]. In contrast,  
54  
55  
56 it inhibits the attachment of Gal-2 [10], suggesting the phosphorylation to take place after the transfer  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 of Gal-2 but before that of GlcA-4. Intriguingly, the sulfation of Gal-2 promotes the transfer of the  
2  
3  
4 first GlcA [10, 11]. Furthermore, prior 4-*O*-sulfation of Gal-3 stimulates the 6-*O*-sulfation of Gal-2  
5  
6  
7 by recombinant human C6ST-1 [38]. Thus, the sulfated linkage region may also contain signals that  
8  
9  
10 influence further sulfation of the linkage region and the repeating disaccharide region as well as  
11  
12  
13 chain polymerization. In fact, sulfation in the vicinity of the linkage region has an influence on the  
14  
15  
16  $\beta$ -*N*-acetylgalactosaminyltransferase activity for chain elongation [39, 40]. However, the biological  
17  
18  
19 significance of modifications to the linkage region has not been fully elucidated, and tools such as  
20  
21  
22 antibodies which recognize these modifications are needed.  
23  
24  
25

26 In this study, a monoclonal antibody, 4E1/D6 (IgM, kappa), which recognizes the  
27  
28  
29 CS-protein linkage region derived from CS of shark cartilage, was developed for the first time. It  
30  
31  
32 recognizes the core pentasaccharide GalNAc-GlcA-Gal-Gal-Xyl: the linkage between the Xyl and  
33  
34  
35 Ser is also essential. A few other amino acids in the vicinity of the Ser residue may be recognized as  
36  
37  
38 well. In addition, the fifth sugar residue (GalNAc-5) from the reducing end is also important. The  
39  
40  
41 2-*O*-phosphate on Xyl is not involved in the recognition. The antibody did not bind the  
42  
43  
44 hexasaccharide glycopeptide fraction  
45  
46  
47 ( $\Delta$ HexA-GalNAc( $\pm$ 4-*O*-sulfate)-GlcA-Gal( $\pm$ 4-*O*-sulfate)-Gal-Xyl-peptides) prepared from CS of  
48  
49  
50 whale cartilage [21], suggesting that it does not recognize the unmodified tetrasaccharide core or  
51  
52  
53 4-*O*-sulfate groups. In contrast, the 6-*O*-sulfate groups on the GalNAc and/or Gal residues appear to  
54  
55  
56 be recognized. The results altogether indicate that the antibody recognizes at least one of the  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 following structures isolated from CS of shark cartilage [25, 26]:

2  
3  
4 GalNAc-GlcA-Gal-Gal(6-*O*-sulfate)-Xyl-Ser,

5  
6  
7 GalNAc(6-*O*-sulfate)-GlcA-Gal-Gal(6-*O*-sulfate)-Xyl-Ser,

8  
9  
10 GalNAc-GlcA-Gal(6-*O*-sulfate)-Gal(6-*O*-sulfate)-Xyl-Ser,

11  
12  
13 GalNAc(6-*O*-sulfate)-GlcA-Gal(6-*O*-sulfate)-Gal(6-*O*-sulfate)-Xyl-Ser. Although the precise epitope  
14  
15  
16 remains unidentified due to the inavailability of specific reagents such as a sulfatase to remove  
17  
18  
19 6-*O*-sulfate groups, this antibody will still be useful for investigating the biological significance of  
20  
21  
22 the 6-*O*-sulfation of the GalNAc and/or Gal residues of the core pentasaccharide.  
23  
24  
25

26 The 6-*O*-sulfated Gal residues in the linkage region have been demonstrated in CS chains  
27  
28  
29 isolated from shark cartilage [26], as well as bovine and human articular cartilage [8, 41]. The  
30  
31  
32 antibody reacted with the CHO-K1 cells as well, suggesting the presence of the structure in the CS  
33  
34  
35 chains on the surface of mammalian cells, although it is extremely difficult to determine using a  
36  
37  
38 chemical method the structure of a minute part of the linkage region of CS/DS or HS/Hep derived  
39  
40  
41 from cultured cells, which contain only one mole per single GAG chain. Notably, however, a  
42  
43  
44 recombinant human chondroitin 6-*O*-sulfotransferase-1 (C6ST-1), which transfers a sulfate to the  
45  
46  
47 C-6-position of GalNAc in the repeating disaccharide region of CS chains, can also transfer a sulfate  
48  
49  
50 group to both the Gal residues in the linkage region [38]. Likewise, a recombinant human  
51  
52  
53 chondroitin 4-*O*-sulfotransferase-1 (C4ST-1), which transfers a sulfate to the C-4-position of  
54  
55  
56 GalNAc in the repeating disaccharide region of CS chains, can also transfer a sulfate group to Gal-3  
57  
58  
59

1 in the linkage region (Mizumoto *et al.*, unpublished results). The 4-*O*-sulfated Gal-3 structure has  
2  
3  
4 been shown in CS from various mammalian tissues and cells including rat chondrosarcoma [7] and  
5  
6  
7 human plasma [42]. The kinase that phosphorylates the Xyl residue has recently been identified as  
8  
9  
10 FAM20B [43]. Thus, the above modifications appear to be widely distributed.  
11

12  
13         Modifications of the linkage region may also act as a marker for the intracellular transport  
14  
15 of CS-PGs to the Golgi compartment for biosynthetic processing or elongation and maturation of the  
16  
17 repeating disaccharide region of CS chains. It is likely that PGs modified with a 4-*O*- or 6-*O*-sulfate  
18  
19  
20 group by the actions of C4ST-1 or C6ST-1 are transported into the suitable Golgi compartment, and  
21  
22  
23 consequently sulfated on GalNAc residues for maturation as well. It would be interesting to  
24  
25  
26 investigate putative binding proteins, which recognize the sulfated Gal residues and may help  
27  
28  
29 acceleration of the transport and/or sulfation of the GalNAc residues of the repeating disaccharide  
30  
31  
32 region. Thus, the sulfation of the Gal residues may reflect a possible difference in the Golgi  
33  
34  
35 compartments in which CS and HS chains are synthesized.  
36  
37  
38  
39  
40  
41

42         It should be noted that C6ST-1 activity is found in medial and trans-Golgi fractions [44].  
43  
44  
45 and that GlcAT-I involved in the synthesis of the linkage region is distributed in both medial and  
46  
47  
48 trans Golgi/trans Golgi networks. This distribution is similar to that of chondroitin-polymerizing  
49  
50  
51 glucuronyltransferase-II activity [45]. It has also been reported that GlcAT-I has a dual Golgi  
52  
53  
54 distribution similar to that of chondroitin polymerizing GlcA transferase-II and distinctly different  
55  
56  
57 from the distribution of the two galactosyltransferases found exclusively in cis-Golgi fractions [45].  
58  
59  
60  
61  
62  
63  
64  
65

1 It has also been reported that xylosyltransferase, galactosyltransferases, and GlcAT-I are distributed  
2  
3  
4 in ER/cis-Golgi, cis-/medial-Golgi, and medial-/trans-Golgi, respectively [46]. These results suggest  
5  
6  
7 that nascent PGs are transported from cis- to trans-Golgi compartments during maturation, and that  
8  
9  
10 the sulfation of the linkage region takes place before the transfer of the first *N*-acetylhexosamine  
11  
12  
13 residue to the tetrasaccharide core and could be a signal for the differential assembly of CS and HS  
14  
15  
16 chains as proposed previously [7, 21, 26].  
17  
18  
19

20 The CHO mutant cells, which are deficient in the glycosyltransferases that synthesize the  
21  
22  
23 linkage region tetrasaccharide core, cannot synthesize either CS/DS or HS/Hep, suggesting the same  
24  
25  
26 glycosyltransferases synthesize the linkage region common to both types of the GAG chains [22, 47,  
27  
28  
29 48]. Therefore, the types of GAG chains to be selectively assembled on the linkage region  
30  
31  
32 tetrasaccharide are determined after or during the construction of the linkage region by these  
33  
34  
35 enzymes. The amino acid sequence around the GAG attachment site (Ser) varies among different  
36  
37  
38 PGs. Therefore, it is unlikely that only the amino acid sequence near the GAG attachment site  
39  
40  
41 determines the type of GAG, although it has some influence [49]. In fact, a PG named serglycine is a  
42  
43  
44 typical example, which can be modified by CS or HS [50].  
45  
46  
47

48 A number of PGs occur in the form of both a PG and a protein without a GAG chain, and  
49  
50  
51 are called part-time PGs [51]. For example, thrombomodulin, a cell surface glycoprotein, occurs both  
52  
53  
54 as a CS-PG ( $\beta$ -thrombomoduline) and as a protein without a CS chain ( $\alpha$ -thrombomodulin), which  
55  
56  
57 has only a tetrasaccharide linkage region, being an immature glycoprotein [52]. The biosynthetic  
58  
59  
60

1 control mechanism to produce such immature PG forms or to interfere with the glycanation step  
2  
3  
4 remains to be investigated. This antibody may also be useful for investigating the biological  
5  
6  
7 functions and processing of part-time PGs.  
8  
9

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



1 **Acknowledgements**  
2

3 This work was supported in part by a Grants-in-aid for Scientific Research (B) (20390019) from the  
4  
5  
6 Ministry of Education, Culture, Sports, Science, and Technology of Japan (MEXT), and for Regional  
7  
8  
9 R&D Proposal-Based Program from Northern Advancement Center for Science & Technology of  
10  
11  
12  
13 Hokkaido Japan.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 **Footnotes**

2  
3  
4 1. Affiliation of the authors

5  
6  
7 Chizuru Akatsu<sup>1</sup>, Duriya Fongmoon<sup>1,2,3</sup>, Shuji Mizumoto<sup>1</sup>, Jean-Claude Jacquinet<sup>4</sup>, Prachya  
8  
9  
10 Kongtawelert<sup>2</sup>, Shuhei Yamada<sup>1,\*</sup>, and Kazuyuki Sugahara<sup>1,\*</sup>

11  
12  
13  
14  
15  
16  
17 (1) Laboratory of Proteoglycan Signaling and Therapeutics, Graduate School of Life Science,  
18  
19  
20 Hokkaido University, Frontier Research Center for Post-Genomic Science and Technology, Nishi  
21  
22  
23 11-choume, Kita 21-jo, Kita-ku, Sapporo, Hokkaido 001-0021, Japan

24  
25  
26 (2) Thailand Excellence Center for Tissue Engineering, Department of Biochemistry, Faculty of  
27  
28  
29 Medicine, Chiang Mai University, Chiang Mai 50200, Thailand

30  
31  
32 (3) Lampang Cancer Center, Department of Medicine, Ministry of Public Health, Lampang 52000,  
33  
34  
35 Thailand

36  
37  
38 (4) Institut de Chimie Organique et Analytique - CNRS UMR 6005, UFR Sciences, Universit  
39  
40  
41 d'Orlans, BP 6759, 45067 Orlans Cedex, France

42  
43  
44  
45 \* E-mail: tjohej@sci.hokudai.ac.jp and k-sugar@sci.hokudai.ac.jp

## References

1. Bishop, J.R., Schuksz, M., Esko, J. D.: Heparan sulphate proteoglycans fine-tune mammalian physiology. *Nature* **446**, 1030-1037 (2007)
2. Sugahara, K., Mikami, T.: Chondroitin/dermatan sulfate in the central nervous system. *Curr. Opin. Struct. Biol.* **17**, 536-545 (2007)
3. Yamada, S., Sugahara, K.: Potential therapeutic application of chondroitin sulfate/dermatan sulfate. *Curr. Drug. Discov. Technol.* **5**, 289-301 (2008)
4. Nadanaka, S., Kitagawa, H.: Heparan sulphate biosynthesis and disease. *J. Biochem.* **144**, 7-14 (2008)
5. Lindahl, U., Rodén, L.: Carbohydrate-protein linkages in proteoglycans of animal, plant and bacterial origin. In: Gottschalk, A. (ed.) *Glycoproteins* pp. 491-517, Elsevier Science Publishing Co., Inc., New York (1972)
6. Sugahara, K., Kitagawa, H.: Recent advances in the study of the biosynthesis and functions of sulfated glycosaminoglycans. *Curr. Opin. Struct. Biol.* **10**, 518-527 (2000)
7. Sugahara, K., Yamashina, I., de Waard, P., van Halbeek, H., Vliegthart, J.F.G.: Structural studies on sulfated glycopeptides from the carbohydrate-protein linkage region of chondroitin 4-sulfate proteoglycans of swarm rat chondrosarcoma. *J. Biol. Chem.* **263**, 10168-10174 (1988)
8. Lauder, R.M., Huckerby, T.N., Nieduszynski, I.A.: Increased incidence of unsulphated and 4-sulphated residues in the chondroitin sulphate linkage region observed by high-pH

- 1 anion-exchange chromatography. *Biochem. J.* **347**, 339-348 (2000)
- 2
- 3
- 4 9. Ueno, M., Yamada, S., Zako, M., Bernfield, M., Sugahara, K.: Structural characterization of
- 5
- 6
- 7 heparan sulfate and chondroitin sulfate of syndecan-1 purified from normal murine mammary
- 8
- 9
- 10 gland epithelial cells. *J. Biol. Chem.* **276**, 29134-29140 (2001)
- 11
- 12
- 13 10. Gulberti, S., Lattard, V., Fondeur, M., Jacquinet, J.C., Mulliert, G., Netter, P., Magdalou, J.,
- 14
- 15
- 16 Ouzzine, M., Fournel-Gigleux, S.: Phosphorylation and sulfation of oligosaccharide substrates
- 17
- 18
- 19 critically influence the activity of human  $\beta$ 1,4-galactosyltransferase 7 (GalT-I) and
- 20
- 21
- 22  $\beta$ 1,3-glucuronosyltransferase I (GlcAT-I) involved in the biosynthesis of the
- 23
- 24
- 25 glycosaminoglycan-protein linkage region of proteoglycans. *J. Biol. Chem.* **280**, 1417-1425
- 26
- 27
- 28 (2005)
- 29
- 30
- 31
- 32 11. Tone, Y., Pedersen, L.C., Yamamoto, T., Izumikawa, T., Kitagawa, H., Nishihara, J., Tamura, J.,
- 33
- 34
- 35 Negishi, M., Sugahara, K.: 2-*O*-Phosphorylation of xylose and 6-*O*-sulfation of galactose in the
- 36
- 37
- 38 protein linkage region of glycosaminoglycans influence the glucuronyltransferase-I activity
- 39
- 40
- 41 involved in the linkage region synthesis. *J. Biol. Chem.* **283**, 16801-16807 (2008)
- 42
- 43
- 44
- 45 12. Ito, Y., Hikino, M., Yajima, Y., Mikami, T., Sirko, S., von Holst, A., Faissner, A., Fukui, S.,
- 46
- 47
- 48 Sugahara, K.: Structural characterization of the epitopes of the monoclonal antibodies 473HD,
- 49
- 50
- 51 CS-56, and MO-225 specific for chondroitin sulfate D-type using the oligosaccharide library.
- 52
- 53
- 54
- 55 *Glycobiology* **15**, 593-603 (2005)
- 56
- 57
- 58 13. Pothacharoen, P., Kalayanamitra, K., Deepa, S.S., Fukui, S., Hattori, T., Fukushima, N.,
- 59
- 60

- 1 Hardingham, T., Kongtawelert, P., Sugahara, K.: Two related but distinct chondroitin sulfate  
2  
3  
4 mimetope octasaccharide sequences recognized by monoclonal antibody WF6. *J. Biol. Chem.*  
5  
6  
7 **282**, 35232-35246 (2007)  
8  
9
- 10 14. Deepa, S.S., Kalayanamitra, K., Ito, Y., Kongtawelert, P., Fukui, S., Yamada, S., Mikami, T.,  
11  
12  
13 Sugahara, K.: Novel sulfated octa- and decasaccharides from squid cartilage chondroitin sulfate  
14  
15  
16  
17 *E. Biochemistry* **46**, 2453-2465 (2007)  
18  
19
- 20 15. Deepa, S.S., Yamada, S., Fukui, S., Sugahara, K.: Structural determination of novel sulfated  
21  
22  
23 octasaccharides isolated from chondroitin sulfate of shark cartilage and their application for  
24  
25  
26  
27 characterizing monoclonal antibody epitopes. *Glycobiology* **17**, 631-645 (2007)  
28  
29
- 30 16. Purushothaman, A., Fukuda, J., Mizumoto, S., ten Dam, G.B., van Kuppevelt, T.H., Kitagawa, H.,  
31  
32  
33 Mikami, T., Sugahara, K.: Functions of chondroitin sulfate/dermatan sulfate chains in brain  
34  
35  
36  
37 development. *J. Biol. Chem.* **282**, 19442-19452 (2007)  
38
- 39 17. Maeda, N., He, J., Yajima, Y., Mikami, T., Sugahara, K., Yabe, T.: Heterogeneity of the  
40  
41  
42 chondroitin sulfate portion of phosphacan/6B4 proteoglycan regulates its binding affinity for  
43  
44  
45  
46 pleiotrophin/heparin binding growth-associated molecule. *J. Biol. Chem.* **278**, 35805-35811  
47  
48  
49 (2003)  
50
- 51 18. Pothacharoen, P., Siriaunkgul, S., Ong-Chai, S., Supabandhu, J., Kumja, P., Wanaphirak, C.,  
52  
53  
54  
55 Sugahara, K., Hardingham, T., Kongtawelert, P.: Raised serum chondroitin sulfate epitope level  
56  
57  
58  
59 in ovarian epithelial cancer. *J. Biochem.* **140**, 517-524 (2006)  
60  
61  
62  
63  
64  
65

- 1 19. ten Dam, G.B., van de Westerlo, E.M., Purushothaman, A., Stan, R.V., Bulten, J., Sweep, F.C.,  
2  
3  
4 Massuger, L.F., Sugahara, K., van Kuppevelt, T.H.: Antibody GD3G7 selected against  
5  
6  
7 embryonic glycosaminoglycans defines chondroitin sulfate-E domains highly up-regulated in  
8  
9  
10 ovarian cancer and involved in vascular endothelial growth factor binding. *Am. J. Pathol.* **171**,  
11  
12  
13 1324-1333 (2007)  
14  
15
- 16 20. Nakagawa, H., Hama, Y., Sumi, T., Li, S.C., Maskos, K., Kalayanamitra, K., Mizumoto, S.,  
17  
18  
19 Sugahara, K., Li, Y.T.: Occurrence of a nonsulfated chondroitin proteoglycan in the dried saliva  
20  
21  
22 of *Collocalia* swiftlets (edible bird's-nest). *Glycobiology* **17**, 157-164 (2007)  
23  
24  
25
- 26 21. Sugahara, K., Masuda, M., Harada, T., Yamashina, I., de Waard, P., Vliegenthart, J.F.G.:  
27  
28  
29 Structural studies on sulfated oligosaccharides derived from the carbohydrate-protein linkage  
30  
31  
32 region of chondroitin sulfate proteoglycans of whale cartilage. *Eur. J. Biochem.* **202**, 805-811  
33  
34  
35 (1991)  
36  
37  
38
- 39 22. Esko, J.D., Stewart, T.E., Taylor, W.H.: Animal cell mutants defective in glycosaminoglycan  
40  
41  
42 biosynthesis. *Proc. Natl. Acad. Sci. U.S.A.* **82**, 3197-3201 (1985)  
43  
44
- 45 23. Sakaguchi, H., Watanabe, M., Ueoka, C., Sugiyama, E., Taketomi, T., Yamada, S., Sugahara, K.:  
46  
47  
48 Isolation of reducing oligosaccharide chains from the chondroitin/dermatan sulfate-protein  
49  
50  
51 linkage region and preparation of analytical probes by fluorescent labeling with  
52  
53  
54 2-aminobenzamide. *J. Biochem.* **129**, 107-118 (2001)  
55  
56  
57
- 58 24. Rio, S., Beau, J.M., Jacquinet, J.C.: Synthesis of sulfated and phosphorylated glycopeptides from  
59  
60  
61

- 1 the carbohydrate-protein linkage region of proteoglycans. *Carbohydr. Res.* **255**, 103-124 (1994)
- 2
- 3
- 4 25. Sugahara, K., Ohi, Y., Harada, T., de Waard, P., Vliegthart, J.F.G.: Structural studies on sulfated
- 5
- 6
- 7 oligosaccharides derived from the carbohydrate-protein linkage region of chondroitin 6-sulfate
- 8
- 9
- 10 proteoglycans of shark cartilage. *J. Biol. Chem.* **267**, 6027-6035 (1992)
- 11
- 12
- 13 26. de Waard, P., Vliegthart, J.F.G., Harada, T., Sugahara, K.: Structural studies on sulfated
- 14
- 15
- 16 oligosaccharides derived from the carbohydrate-protein linkage region of chondroitin 6-sulfate
- 17
- 18
- 19 proteoglycans of shark cartilage. *J. Biol. Chem.* **267**, 6036-6043 (1992)
- 20
- 21
- 22
- 23 27. Ludwigs, U., Elgavish, A., Esko, J.D., Meezan, E., Rodén, L.: Reaction of unsaturated uronic
- 24
- 25
- 26 acid residues with mercuric salts. *Biochem. J.* **245**, 795-804 (1987)
- 27
- 28
- 29 28. Kusche, M., Lindahl, U., Enerbäck, L., Rodén, L.: Identification of oversulphated
- 30
- 31
- 32 galactosaminoglycans in intestinal-mucosal mast cells of rats infected with the nematode worm
- 33
- 34
- 35 *Nippostrongylus brasiliensis*. *Biochem. J.* **253**, 885-893 (1988)
- 36
- 37
- 38
- 39 29. Yoshida, K., Arai, M., Kohno, Y., Maeyama, K., Miyazono, H., Kikuchi, H., Morikawa, K.,
- 40
- 41
- 42 Tawada, A., Suzuki, S.: Activity of bacterial eliminases towards dermatan sulphates and
- 43
- 44
- 45 dermatan sulphate proteoglycan. In: Scott, J.E. (ed.) *Dermatan sulphate proteoglycans* pp. 55-70,
- 46
- 47
- 48 Portland Press, London
- 49
- 50
- 51 30. Yamagata, T., Saito, H., Habuchi, O., Suzuki, S.: Purification and properties of bacterial
- 52
- 53
- 54 chondroitinases and chondrosulfatases. *J. Biol. Chem.* **243**, 1523-1535 (1968)
- 55
- 56
- 57
- 58 31. Bitter, T., Muir, H.M.: A modified uronic acid carbazole reaction. *Anal. Biochem.* **4**, 330-334
- 59
- 60
- 61
- 62
- 63
- 64
- 65

1 (1962)  
2  
3

4 32. May, R.J., Beenhouwer, D.O., Scharff, M.D.: Antibodies to keyhole limpet hemocyanin  
5  
6 cross-react with an epitope on the polysaccharide capsule of *Cryptococcus neoformans* and other  
7  
8 carbohydrates. J. Immunol. **171**, 4905-4912 (2003)  
9  
10

11  
12  
13 33. Heinegård, D.: Hyaluronidase digestion and alkaline treatment of bovine tracheal cartilage  
14  
15 proteoglycans. Biochim. Biophys. Acta **285**, 193-207 (1972)  
16  
17

18  
19  
20 34. Sugahara, K., Kojima, T.: Specificity studies of bacterial sulfatases by means of structurally  
21  
22 defined sulfated oligosaccharides isolated from shark cartilage chondroitin sulfate D. Eur. J.  
23  
24 Biochem. **239**, 865-870 (1996)  
25  
26

27  
28  
29 35. Nakanishi, M., Moriyama, A., Narita, Y., Sasaki, M.: Aminopeptidase M from human liver. J.  
30  
31 Biochem. **106**, 818-825 (1989)  
32  
33

34  
35  
36 36. Pétra, P.H.: Bovine procarboxypeptidase and carboxypeptidase A. Methods Enzymol. **19**,  
37  
38 460-503 (1970)  
39  
40

41  
42 37. Moses, J., Oldberg, Å., Fransson, L.-Å.: Initiation of galactosaminoglycan biosynthesis. Separate  
43  
44 galactosylation and dephosphorylation pathways for phosphoxylosylated decorin protein and  
45  
46 exogenous xyloside. Eur. J. Biochem. **260**, 879-884 (1999)  
47  
48

49  
50  
51 38. Kitagawa, H., Tsutsumi, K., Ikegami-Kuzuhara, A., Nadanaka, S., Goto, F., Ogawa, T., Sugahara,  
52  
53 K.: Sulfation of the galactose residues in the glycosaminoglycan-protein linkage region by  
54  
55 recombinant human chondroitin 6-O-sulfotransferase-1. J. Biol. Chem. **283**, 27438-27443 (2008)  
56  
57  
58  
59



- 1 39. Kitagawa, H., Tsutsumi, K., Ujikawa, M., Goto, F., Tamura, J., Neumann, K. W., Ogawa, T.,  
2  
3  
4 Sugahara, K.: Regulation of chondroitin sulfate biosynthesis by specific sulfation. *Glycobiology*  
5  
6  
7 **7**, 531-537 (1997)  
8  
9
- 10 40. Lidholt, K., Fjelstad, M., Lindahl, U., Goto, F., Ogawa, T., Kitagawa, H., Sugahara, K.:  
11  
12  
13 Assessment of glycosaminoglycan-protein linkage tetrasaccharides as acceptors for GalNAc- and  
14  
15  
16 GlcNAc-transferases from mouse mastocytoma. *Glycoconj. J.* **14**, 737-742 (1997)  
17  
18  
19
- 20 41. Lauder, R.M., Huckerby, T.N., Brown, G.M., Bayliss, M.T., Nieduszynski, I.A.: Age-related  
21  
22  
23 changes in the sulphation of the chondroitin sulphate linkage region from human articular  
24  
25  
26 cartilage aggrecan. *Biochem. J.* **358**, 523-528 (2001)  
27  
28  
29
- 30 42. Yamada, S., Oyama, M., Kinugasa, H., Nakagawa, T., Kawasaki, T., Nagasawa, S., Khoo, K.-H.,  
31  
32  
33 Morris, H.R., Dell, A., Sugahara, K.: The sulphated carbohydrate-protein linkage region isolated  
34  
35  
36 from chondroitin 4-sulphate chains of inter- $\alpha$ -trypsin inhibitor in human plasma. *Glycobiology* **5**,  
37  
38  
39 335-341 (1995)  
40  
41
- 42 43. Koike, T., Izumikawa, T., Tamura, J., Kitagawa, H.: FAM20B is a kinase that phosphorylates  
43  
44  
45 xylose in the glycosaminoglycan-protein linkage region. *Biochem. J.* **421**, 157-162 (2009)  
46  
47  
48
- 49 44. Sugumaran, G., Silbert, J.E.: Subfractionation of chick embryo epiphyseal cartilage Golgi. *J. Biol.*  
50  
51  
52 *Chem.* **266**, 9565-9569 (1991)  
53  
54
- 55 45. Sugumaran, G., Katsman, M., Silbert, J.E.: Subcellular co-localization and potential interaction  
56  
57  
58 of glucuronosyltransferases with nascent proteochondroitin sulphate at Golgi sites of chondroitin  
59  
60  
61

- 1 synthesis. *Biochem. J.* **329**, 203-208 (1998)
- 2
- 3
- 4 46. Prydz, K., Dalen, K.T.: Synthesis and sorting of proteoglycans. *J. Cell Sci.* **113**, 193-205 (2000)
- 5
- 6
- 7 47. Esko, J.D., Weinke, J.L., Taylor, W.H., Ekborg, G., Rodén L., Anantharamaiah, G., Gawish, A.:
- 8
- 9
- 10 Inhibition of chondroitin and heparan sulfate biosynthesis in Chinese hamster ovary cell mutants
- 11
- 12
- 13 defective in galactosyltransferase I. *J. Biol. Chem.* **262**, 12189-12195 (1987)
- 14
- 15
- 16 48. Bai, X., Wei, G., Sinha, A., Esko J.D.: Chinese hamster ovary cell mutants defective in
- 17
- 18
- 19 glycosaminoglycan assembly and glucuronosyltransferase I. *J. Biol. Chem.* **274**, 13017-13024
- 20
- 21
- 22 (1999)
- 23
- 24
- 25
- 26 49. Esko, J.D., Zhang, L.: Influence of core protein sequence on glycosaminoglycan assembly. *Curr.*
- 27
- 28
- 29 *Opin. Struct. Biol.* **6**, 663-670 (1996)
- 30
- 31
- 32 50. Kolset, S.O., Tveit, H.: Serglycin – structure and biology. *Cell. Mol. Life Sci.* **65**, 1073-1085
- 33
- 34
- 35 (2008)
- 36
- 37
- 38
- 39 51. Fransson, L.-Å.: Structure and function of cell-associated proteoglycans. *Trends Biochem. Sci.*
- 40
- 41
- 42 **12**, 406-411 (1987)
- 43
- 44
- 45 52. Nadanaka, S., Kitagawa, H., Sugahara K.: Demonstration of the immature glycosaminoglycan
- 46
- 47
- 48 tetrasaccharide sequence GlcA $\beta$ 1–3Gal $\beta$ 1–3Gal $\beta$ 1–4Xyl on recombinant soluble human
- 49
- 50
- 51  $\alpha$ -thrombomodulin. *J. Biol. Chem.* **273**, 33728-33734 (1998)
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65

1 **Figure legends**  
2  
3

4 **Fig. 1** Reactivity of the antibody 4E1/D6 toward various PG preparations. The reactivity of the  
5  
6 antibody 4E1/D6 with various PGs was analyzed by ELISA. PGs from salmon nasal cartilage,  
7  
8 rayfish cartilage, bird nest, chicken cartilage, bovine nasal cartilage, whale cartilage (10 µg each) and  
9  
10 the linkage hexasaccharide peptide (hexa-pep) fraction derived from shark cartilage CS (0.5 ug) were  
11  
12 individually immobilized to the wells, and processed for incubation with 4E1/D6 followed by  
13  
14 alkaline phosphatase-linked goat anti-mouse Ig(G+M) (diluted 3,000-fold). Bound antibodies were  
15  
16 detected by the addition of *p*-nitrophenylphosphate as a substrate. The reactivity is given relative to  
17  
18 the linkage hexasaccharide-peptide fraction from shark cartilage CS.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

32 **Fig. 2** Reactivity of the antibody 4E1/D6 toward various linkage oligosaccharide-peptide fractions.  
33  
34 The linkage hexa-, penta-, and tetrasaccharide-peptide fractions derived from shark cartilage CS and  
35  
36 the linkage hexasaccharide-peptide fraction from whale cartilage CS (0.5 µg each) were immobilized  
37  
38 to the wells, and the reactivity of 4E1/D6 to the immobilized fractions was analyzed by ELISA as  
39  
40 described in the legend to Figure 1. The assay was performed in duplicate and values represent the  
41  
42 mean ± S.D. The reactivity is given relative to the linkage hexasaccharide-peptide fraction from  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58 **Fig. 3** Reactivity of the antibody 4E1/D6 toward the linkage hexasaccharide-peptide fraction treated  
59  
60  
61  
62  
63  
64  
65

1 with alkali or peptidases. The linkage hexasaccharide-peptide (hexa-pep) fraction from shark  
2  
3  
4 cartilage CS was treated with alkali, or digested with aminopeptidase or carboxypeptidase. Each  
5  
6  
7 sample was used as an inhibitor (4 nmol each) for the binding of 4E1/D6 to the immobilized  
8  
9  
10 un-treated linkage hexasaccharide-peptide fraction (0.5  $\mu$ g) for the competitive ELISA. The  
11  
12  
13 un-treated linkage hexasaccharide-peptide fraction (4 nmol) was also used as a control inhibitor.  
14  
15  
16 Bound antibodies were visualized as described in the legend to Figure 1. This assay was performed  
17  
18  
19 in duplicate, and all values are expressed as a percentage of the reactivity observed without inhibitors  
20  
21  
22 and represent the mean  $\pm$ S.D.  
23  
24  
25  
26  
27  
28

29 **Fig. 4** Reactivity of the antibody 4E1/D6 toward the linkage hexasaccharide-peptide fraction treated  
30  
31 with phosphatase or chondro-4-sulfatase. The linkage hexasaccharide-peptide fraction (500 pmol  
32  
33 each) was treated with alkali phosphatase or chondro-4-sulfatase and each digest was immobilized to  
34  
35  
36 the well. The reactivity of 4E1/D6 toward the digest was analyzed by ELISA. Bound antibodies were  
37  
38  
39 visualized as described in the legend to Figure 1. The reactivity is given relative to the linkage  
40  
41  
42 hexasaccharide-peptide fraction from shark cartilage CS. The assay was performed in duplicate and  
43  
44  
45 values represent the mean  $\pm$  S.D.  
46  
47  
48  
49  
50  
51  
52  
53  
54

55 **Fig. 5** Action of chondro-4-sulfatase on the structurally defined linkage hexasaccharide. The  
56  
57  
58 structurally defined linkage hexasaccharide,  
59  
60



1 by immunofluorescence flow cytometry. A HS-specific monoclonal antibody (F58/10E4) was used as  
2  
3  
4 a control. *Light gray* and *dark gray histograms* represent the 4E1/D6 and F58-10E4-binding,  
5  
6  
7 respectively, as detected with Alexa Fluor 488<sup>®</sup>-conjugated anti-mouse IgM antibody. *Empty*  
8  
9  
10 *histograms* show the background fluorescence.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Figure1

[Click here to download high resolution image](#)




Figure2

[Click here to download high resolution image](#)






Figure3

[Click here to download high resolution image](#)




Figure4

[Click here to download high resolution image](#)




Figure5  
[Click here to download high resolution image](#)




Figure6

[Click here to download high resolution image](#)





Figure7

[Click here to download high resolution image](#)



**Table 1.** Structure of the major components in the linkage hexasaccharide fractions purified from CS of shark cartilage and whale cartilage

$\Delta\text{HexA}\alpha 1\text{-3GalNAc}\beta 1\text{-4GlcA}\beta 1\text{-3Gal}\beta 1\text{-3Gal}\beta 1\text{-4Xyl}\beta 1\text{-O-Ser}$						
<u>6</u>	<u>5</u>	<u>4</u>	<u>3</u>	<u>2</u>	<u>1</u>	
CS from shark cartilage <sup>a</sup>						
Modifications <sup>b</sup>						Proportion <sup>c</sup>
<u>6</u>	<u>5</u>	<u>4</u>	<u>3</u>	<u>2</u>	<u>1</u>	(mol%)
—	—	—	—	—	—	13.1
—	6S	—	—	—	—	8.3
—	4S	—	—	—	—	2.1
—	—	—	—	—	2P	6.7
—	6S	—	—	—	2P	3.4
—	—	—	—	6S	—	5.3
—	6S	—	—	6S	—	4.8
—	4S	—	—	6S	—	1.5
—	—	—	6S	6S	—	5.5
—	6S	—	6S	6S	—	37.4
—	4S	—	6S	6S	—	9.1
—	6S	—	4S	6S	—	1.1
—	4S	—	4S	6S	—	1.6
CS from whale cartilage <sup>d</sup>						
Modifications <sup>b</sup>						Proportion <sup>c</sup>
<u>6</u>	<u>5</u>	<u>4</u>	<u>3</u>	<u>2</u>	<u>1</u>	(mol%)
—	—	—	—	—	—	21
—	6S	—	—	—	—	16
—	4S	—	—	—	—	36
—	4S	—	4S	—	—	27

<sup>a</sup>Data are from Sugahara *et al.* 1992 [25] and de Waard *et al.* [26].

<sup>b</sup>The modifications in each monosaccharide residue are shown in the table. The numbers refer to the corresponding residues in the linkage structures shown above. 4S, 6S, and 2P stand for 4-*O*-sulfate, 6-*O*-sulfate, and 2-*O*-phosphate, respectively.

<sup>c</sup>The proportion of each structure is expressed as a molar percentage of the total linkage hexasaccharide fraction.

<sup>d</sup>Data are from Sugahara *et al.* 1991 [21].